Utiva Named #1 for UTI Prevention by Canadian Doctors and Pharmacists

PICKERING, ON – April 02, 2026 – In a significant endorsement from the Canadian medical community, Utiva has been named the number one recommended brand for urinary tract infection (UTI) prevention by both physicians and pharmacists. The recognition comes from the prestigious 2026 OTC Counselling and Recommendations Survey, an annual poll conducted by EnsembleIQ that gauges the professional opinions of healthcare providers across the country.

This top ranking, covering both English and French Canada, positions the Pickering-based brand as a leader in a crucial area of public health. For the millions of Canadians, predominantly women, who suffer from recurrent UTIs, the endorsement provides a clear signal of trust in a marketplace often crowded with unverified claims. The achievement underscores a broader shift in healthcare towards evidence-based, natural alternatives to manage chronic conditions.

Beyond the Juice: A New Standard of Clinical Rigor

The supplement aisle is filled with cranberry products promising UTI relief, but Utiva’s ascent to the top is rooted in a commitment to clinical precision that sets it apart. The company’s flagship product, Utiva UTI Control®, is built around a specific, clinically validated dose of its active ingredient: 36 milligrams of Proanthocyanidins (PACs), the natural compounds in cranberries responsible for preventing bacteria from adhering to the bladder wall.

"We're honoured to be recognized as Canada's #1 brand for UTI prevention by physicians and pharmacists," said Faraz Nomani, Co-Founder of Utiva. "Unlike many cranberry supplements that do not verify PAC content using standards in clinical research, Utiva delivers the clinically studied dose to prevent UTIs."

This isn't just marketing language. The key is in the measurement. Utiva uses the DMAC/A2 method, an internationally recognized standard for quantifying PACs. This ensures that every dose contains the precise amount of the active ingredient shown to be effective in scientific studies. Many competing products on the market fail to specify their PAC content or use a standardized measurement, leaving consumers and healthcare professionals uncertain about their potency. This dedication to verifiable efficacy has clearly resonated with Canadian doctors and pharmacists, who are increasingly prioritizing evidence when making recommendations.

The Science Behind the Recommendation

The trust placed in Utiva by medical professionals is not arbitrary; it is backed by a growing body of scientific evidence. The recommendation for a daily intake of at least 36 mg of PACs is supported by numerous studies and medical guidelines as the minimum effective dose for preventing the bacterial adhesion that leads to UTIs.

A 2023 meta-analysis confirmed that a daily intake of 36 mg of PACs significantly reduced the risk of UTIs. Furthermore, a landmark Cochrane Review, often considered the gold standard in evidence-based medicine, concluded that a 36 mg bioactive PAC supplement was as effective as low-dose antibiotics for UTI prevention—a critical finding amid growing global concerns over antibiotic resistance.

The Canadian Urological Association (CUA) itself recommends cranberry supplements as a non-antibiotic option to reduce the risk of recurrent UTIs. Healthcare professionals now frequently guide patients away from sugary cranberry juice cocktails, which offer inconsistent PAC levels, and towards standardized supplements. A standardized dose provides a reliable preventative strategy without the high sugar content, a crucial consideration for many patients, including those with diabetes.

This professional endorsement signals a move towards empowering patients with effective, non-pharmaceutical tools. By recommending a product with proven ingredients and transparent dosing, doctors and pharmacists are helping patients take a proactive role in managing their health and breaking the painful cycle of recurrent infections.

A Canadian Health Success Story

Utiva's achievement is also a notable Canadian business success story. The brand is part of the portfolio of Szio+ Inc., a healthcare company founded in 2018 by Faraz Nomani and Derek Oh. With a mission to build trusted brands using natural, clinically proven ingredients, Szio+ Inc. has seen remarkable growth. For three consecutive years, it has been named one of Canada's Top Growing Companies by The Globe and Mail's Report on Business, a testament to its effective strategy and market resonance.

Operating from its base in Ontario and manufacturing its products locally, the company has successfully scaled its distribution network. Today, Utiva products are available in over 5,000 pharmacies and health food stores across Canada and are trusted by more than 20,000 doctors. This widespread availability ensures that the professionally recommended solution is also an accessible one for Canadians seeking relief.

The company’s success demonstrates a powerful model for the natural health product industry: combine rigorous scientific validation with strong healthcare professional engagement and widespread consumer access. By focusing on education for both practitioners and the public, Szio+ Inc. has built a foundation of trust that now culminates in this number one ranking.

What This Means for Consumers

For anyone who has stood in a pharmacy aisle feeling overwhelmed by choices for UTI prevention, this news offers clarity. The top recommendation from Canadian physicians and pharmacists acts as a powerful guide, cutting through the noise of marketing claims to highlight a product validated by scientific evidence and professional consensus.

The ranking serves as a reminder of the importance of looking beyond the front of the box. Consumers are encouraged to seek out products that specify the dose of their active ingredients, like the 36 mg of PACs in Utiva, and are backed by standardized measurement methods. It is crucial, however, to remember that supplements like Utiva are intended for prevention, not for the treatment of an active UTI, which requires medical diagnosis and typically a course of antibiotics.

As Canadians continue to seek proactive and reliable ways to manage their health, the clear endorsement from the nation's medical experts provides a trusted path forward for preventing one of the world's most common bacterial infections.